Drawing from his 27 years in the pharma industry, Chris Garabedian shares useful lessons for combining business savvy and scientific leadership in drug development.
This French company is addressing vertigo and hearing loss inside the inner ear.
Beginning her career with the query — how does biology cause disease? — Vicki Sato progressed to business, turning scientific understanding into new therapeutic drugs. Sato has been a biopharma leader since the industry’s formative years, helping drive the growth of Biogen and Vertex, and she is still guiding new companies today.
Our company to watch this month is Landos Biopharma, which is aiming for better targeting and better delivery of treatments for GI and other autoimmune diseases.
Her mother was the first woman of her village in Cyprus to go to high school. Anna Protopapas shared her mother’s drive to bypass all barriers, and she now runs the biopharma company Mersana, after many years in the leadership of Millennium and Takeda.
Reata refused to take what seemed like a dead-end trial as a losing proposition. Instead, the company went to work mining the trial for the very insights that subsequently saved it.
CytoDyn’s expressed ambitions seem bold but reasonably free of hyperbole. It is only natural to hope for the best possible outcome here, considering the obvious need for new HIV and other immunological therapies.
AmpliPhi Biosciences is pushing bacteriophage-therapy development for drug-resistant infections — not to replace, but possibly to augment antibiotics.
We check in with the companies we profiled from this section in 2017 to see what has changed … if anything.
Cydan is using a new business model in which they challenge the ways companies dealt with orphan drugs in the past.
Here, I aim to offer some additional ideas for how companies can best describe themselves and their products — and how PR agents, journalists, and others might describe them — by achieving the opposite of hype: clarity.
This month’s Company To Watch is 10-person Zavante, which is challenging drug resistance with a retooled antibiotic and a broad mechanism of action.
In this series on "Life Science Leadership In Action," we discuss PolarityTE, which focuses on regenerating lost tissues in their original complex forms.
In my travels, I’ve especially noted three areas of unavoidable transformation due to forces quite beyond the industry’s control: women’s advocacy, the drug-pricing stalemate, and the new politics.
